AbbVie HEOR Expert Notes Lack of Diversity Negatively Impacts Clinical Trials, RWD Offers Possible Solution

Vice President and Global Head of Health Economics and Outcomes Research (HEOR) at AbbVie Dr. Chris Boone notes that the continued lack of diversity in clinical trials negatively impacts drug development. Moderna’s failure to include diverse candidates for its COVID-19 vaccine trial was the most recent widely publicized example of this lack of inclusion. Earlier this week, Dr. Boone spoke at the annual HIMSS conference and emphasized how real world data (RWD) can address this gap.

Dr. Boone remarks, “Cultural, ethical, regulatory and financial concerns serve as significant barriers to progress,” adding, “At the center is a lack of trust.” Read more here.

(Source: Susan Morse, Healthcare Finance, 8/10/21)